Alicia Austin, MD
Psychiatry · Birmingham, ALNPI 1124237243
Payments from drug & device makers
Across 146 payments — averaging $16.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Indivior Inc.$351
- AbbVie$294
- Otsuka America Pharmaceutical, Inc.$177
- Takeda Pharmaceuticals U.S.A., Inc.$156
- Johnson & Johnson$151
- Sunovion Pharmaceuticals Inc.$117
- plus $1K from 30 others
What the payments were for
- Food & beverage$2,427100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Indivior Inc. | 14 | $351 |
| AbbVie(2 entities) | 20 | $294 |
| Otsuka America Pharmaceutical, Inc. | 12 | $177 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $156 |
| Johnson & Johnson | 11 | $151 |
| Sunovion Pharmaceuticals Inc. | 10 | $117 |
| Orexo US, Inc. | 6 | $94 |
| Teva Pharmaceuticals USA, Inc. | 6 | $88 |
| Scilex Pharmaceuticals Inc. | 5 | $83 |
| Alkermes, Inc. | 4 | $82 |
| Lundbeck LLC | 4 | $80 |
| Avanir Pharmaceuticals, Inc. | 5 | $77 |
| Ironshore Pharmaceuticals Inc. | 3 | $67 |
| Shire North American Group Inc | 4 | $60 |
| Biotronik NRO, Inc. | 2 | $58 |
| Bausch Health US, LLC | 3 | $55 |
| SPR Therapeutics, Inc | 6 | $51 |
| Medtronic(2 entities) | 2 | $40 |
| Arbor Pharmaceuticals, Inc. | 2 | $37 |
| Adlon Therapeutics L.p. | 2 | $37 |
| Pacira Therapeutics, Inc. | 1 | $26 |
| Braeburn Inc. | 1 | $22 |
| Vanda Pharmaceuticals Inc. | 1 | $22 |
| Vertex | 1 | $22 |
| Almatica Pharma LLC | 1 | $21 |
| Jazz Pharmaceuticals Inc. | 1 | $18 |
| Acadia Pharmaceuticals Inc | 1 | $17 |
| Pfizer | 1 | $17 |
| Zyla Life Sciences, Inc. | 1 | $16 |
| Vertical Pharmaceuticals, LLC | 1 | $15 |
| Biodelivery Sciences International, Inc. | 1 | $14 |
| Redhill Biopharma Inc. | 1 | $14 |
| Supernus Pharmaceuticals, Inc. | 1 | $14 |
| Neurocrine Biosciences, Inc. | 1 | $13 |
| Rhodes Pharmaceuticals L.p. | 1 | $12 |
| Kaleo, Inc. | 1 | $11 |
How this compares
$2,427 in reported general payments places this provider in the 70th percentile of 400 psychiatry providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 827 | $189,441 |
| RexultiBrexpiprazole | 28 | $53,484 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 54 | $34,352 |
| ZubsolvBuprenorphine Hcl/Naloxone Hcl | 40 | $23,138 |
| Buprenorphine Hcl | 59 | $4,425 |
| Lisdexamfetamine Dimesylate | 13 | $3,254 |
| Atomoxetine Hcl | 12 | $1,981 |
| Aripiprazole | 44 | $1,594 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 37 | $1,527 |
| Cevimeline Hcl | 11 | $1,502 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 12 | $1,423 |
| Bupropion XlBupropion Hcl | 58 | $1,178 |
| Vilazodone Hcl | 11 | $1,124 |
| Duloxetine Hcl | 52 | $1,025 |
| Lamotrigine | 63 | $1,012 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $177 | $53,48428 claims |
| Indivior Inc.Suboxone | $351 | $34,35254 claims |
| Orexo US, Inc.Zubsolv | $94 | $23,13840 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 400 psychiatry providers in Alabama.
Other psychiatry in Birmingham
- Matthew MacalusoBirmingham$2.8M
- Richard SheltonBirmingham$2.4M
- Armand SchachterBirmingham$758K
- Stephen HughesBirmingham$683K
- Leesha Ellis CoxBirmingham$653K
- Godehard OepenBirmingham$516K
- Melissa KarrhBirmingham$51K
- Santosh PillaiBirmingham$39K
- Jennifer HadleyBirmingham$27K
- Kerry ClearyBirmingham$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.